相关实验视频

Updated: Jul 25, 2026

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

未定位的代谢学确定了英多尔-3-酸以缓解大动脉剖析中的Ang II诱导的内皮功能障碍

Qi Wang¹, Hui Lv¹, Mierxiati Ainiwan¹

¹Department of Cardiology, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Ürümqi, China.

Molecular and cellular biochemistry

|March 15, 2024

概括

印-3-烯酸 (IPA),一个托代谢物,在大动脉剖析 (AD) 中显著降低. 用IPA补充剂通过在小鼠模型中减轻内皮功能障碍来保护AD.

科学领域:

代谢学代谢学代谢学
心血管研究研究心血管研究
微生物组与宿主之间的相互作用

背景情况:

印-3-酸 (IPA) 是酸的肠道微生物代谢物,对心血管疾病 (CVD) 和神经再生至关重要.
IPA在大动脉解剖 (AD) 病变发生过程中的特定作用仍然在很大程度上未被探索.
内皮功能障碍是AD发展的关键因素.

研究的目的:

调查IPA在大动脉解剖 (AD) 病变发生过程中的作用.
阐明IPA在AD中影响内皮功能障碍的潜在机制.

主要方法:

非向的血代谢组来比较AD患者和健康对照组.
网络药理学和分子对接,以预测IPA的分子目标.
在体内 (BAPN/Ang II的小鼠模型) 和体内 (HUVECs) 实验以验证机制.

主要成果:

在AD患者中,IPA被确定为托芬代谢物中最显著降低的代谢物.
IPA的使用抑制了 ангиотензинII诱导的亡,反应性氧物种 (ROS) 生成,炎症和内皮紧密结的丧失.
在小鼠模型中,IPA补充剂减轻了AD的发生和严重程度.

结论:

这项研究揭示了肠道微生物群代谢物IPA和大动脉剖析 (AD) 之间的新兴关联.
IPA通过减轻内皮功能障碍来证明对AD的保护作用.
IPA代表了管理AD的潜在治疗目标.

关键词:

动脉剖析是一个大动脉剖析.内皮质功能障碍内皮质功能障碍印度尔-3-烯酸是一种酸.网络药理学网络药理学没有针对性的代谢组分.

更多相关视频

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

Measurement of Pulse Propagation Velocity, Distensibility and Strain in an Abdominal Aortic Aneurysm Mouse Model

Measurement of Pulse Propagation Velocity, Distensibility and Strain in an Abdominal Aortic Aneurysm Mouse Model

Published on: February 23, 2020

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Mitral Regurgitation III: Medical Management

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...

Aortic Regurgitation III: Medical Management

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...